FDA Trials And Tribulations With Connect Biopharma's Barry Quart

Business Of Biotech

We love to hear from our listeners. Send us a message.

On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving the company from China to San Diego, why a U.S. financial reporting structure helps attract investors, and how Connect is finding the white spaces in respiratory disease -- the company's lead candidate is a biologic drug targeting acute asthma and COPD exacerbations.

This episode of the Business of Biotech is brought to you by Ecolab.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. Episode Introduction and Sponsor Message (00:00:00)

2. Meet Barry Cord and ConnectBiopharma (00:00:44)

3. Early Career and FDA Evolution (00:01:55)

4. The Discovery of Xerampic for Gout (00:05:16)

5. Heron Therapeutics and Pain Management (00:09:26)

6. ConnectBio and Ratamicabart Development (00:16:30)

7. Relocating from China to San Diego (00:24:10)

8. FDA Engagement and Future Priorities (00:54:31)